<< Back
Vitae Pharmaceuticals is ranked #2 in The Scientist magazine’s annual “Best Places to Work” survey
  • Vitae ranked second overall in life sciences industry; highest-ranked U.S. company
  • Survey measured responses of more than 200 companies worldwide

Fort Washington, PA, June 12, 2013 – Vitae Pharmaceuticals, Inc., a clinical‐stage biopharmaceutical company discovering and developing novel, small molecule, best‐in‐class compounds, today announced that the company ranked second among life sciences companies in the 11th annual Best Places to Work in Industry survey conducted by The Scientist. Vitae is the highest-ranked U.S. company on the list, which is based on a detailed survey taken by scientists at life sciences companies and research institutions.

“Vitae’s success in creating rapid discovery breakthroughs for important drug targets is driven by the powerful combination of a highly talented scientific team, a proprietary structure-based design technology, a shared value system and a truly amazing culture,” said Jeff Hatfield, Vitae’s President and CEO. “Vitae’s team-based culture leads to a stimulating, fast and uniquely integrated work environment. Vitae takes pride in, and is at its best, taking on the biggest and most valuable discovery targets, including our rapidly advancing program for RORgt in immunology.”

The web-based survey included responses from 240 companies worldwide. Respondents were asked to assess their working environment according to 43 criteria in eight categories including research environment, management, integrity, job satisfaction, communications, and training and development. The overall rankings were based on the average score per company across all factors.

The full article with detailed survey results and methodology can be found in the June issue of The Scientist and is available online at www.the-scientist.com.

About The Scientist
The Scientist,the award-winning magazine of the life sciences, has informed and entertained life science professionals around the world for more than 20 years. We provide print and online coverage of the latest developments in the life sciences including trends in research, new technology, news, business and careers. We reach the leading researchers in academia and industry who are interested in maintaining a broad view of the life sciences by reading insightful articles that are current, concise, accurate and entertaining.

For more information about The Scientist, visit www.the-scientist.com.

About Vitae Pharmaceuticals
Vitae Pharmaceuticals is a clinical-stage biopharmaceutical company discovering and developing a portfolio of novel, small molecule, best-in-class compounds that address important disease areas, including chronic kidney disease, diabetes, Alzheimer’s disease, and inflammation / immunology.

Vitae excels at structure-based drug discovery and combines a proprietary technical platform with the insight of world class scientists to advance best-in-class compounds for high value, hard-to-drug targets. The accuracy and speed of Vitae’s drug discovery platform has enabled the company to discover and advance attractive compounds in multiple therapeutics areas in a rapid and highly capital efficient manner.

For additional information, please visit the company’s website at www.vitaepharma.com.

Tony Plohoros


"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Vitae Pharmaceuticals Inc's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.